Who are Peginterferon alfa 2's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Intron A, Peginterferon alfa-2a with Ribavirin, Pegylated interferon alpha 2, PegIFN alfa-2a, Peginterferon alfa 2 A, Peginterferon alfa-2a 40KD and Ribavirin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/peginterferon-alfa-2.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Peginterferon alfa 2 — Competitive Intelligence Brief

Peginterferon alfa 2 (Peginterferon alfa 2) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interferon alpha. Area: Immunology, Virology, Oncology.

marketed Interferon alpha Interferon-alpha receptor (IFNAR) Immunology, Virology, Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Peginterferon alfa 2 (Peginterferon alfa 2) — Dr. Conrado Fernandez. Peginterferon alfa-2 is an interferon that activates the immune system to fight viral infections and certain cancers by binding to interferon-alpha receptors on immune cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Peginterferon alfa 2 TARGET	Peginterferon alfa 2	Dr. Conrado Fernandez	marketed	Interferon alpha	Interferon-alpha receptor (IFNAR)
Intron A	INTERFERON ALFA-2B	Merck & Co.	marketed	Interferon alpha		1986-01-01
Peginterferon alfa-2a with Ribavirin	Peginterferon alfa-2a with Ribavirin	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	marketed	Interferon alpha with nucleoside analog	Interferon-alpha receptor (IFNAR); HCV RNA-dependent RNA polymerase
Pegylated interferon alpha 2	Pegylated interferon alpha 2	Ain Shams University	marketed	Interferon alpha	Interferon-alpha receptor (IFNAR)
PegIFN alfa-2a	PegIFN alfa-2a	The Second Affiliated Hospital of Chongqing Medical University	marketed	Pegylated interferon alpha	Interferon-alpha receptor (IFNAR)
Peginterferon alfa 2 A	Peginterferon alfa 2 A	Dr. Conrado Fernandez	marketed	Interferon alpha	Interferon-alpha receptor (IFNAR)
Peginterferon alfa-2a 40KD and Ribavirin	Peginterferon alfa-2a 40KD and Ribavirin	NORDynamIC Study Group	marketed	Interferon alpha with nucleoside analog	Interferon-alpha receptor (IFNAR); viral RNA-dependent RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interferon alpha class)

Dr. Conrado Fernandez · 2 drugs in this class
Ain Shams University · 1 drug in this class
Beijing 302 Hospital · 1 drug in this class
Foundation for Liver Research · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
Kexing Biopharm Co., Ltd. · 1 drug in this class
Merck & Co. · 1 drug in this class
ANRS, Emerging Infectious Diseases · 1 drug in this class
Vertex Pharmaceuticals Incorporated · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Peginterferon alfa 2 — Competitive Intelligence Brief. https://druglandscape.com/ci/peginterferon-alfa-2. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab